AQST - Aquestive Pharmanovia add territories to market seizure drug Libervant

2023-03-29 09:15:13 ET

• Aquestive Therapeutics ( NASDAQ: AQST ) expanded its exclusive license and supply agreement with Atnahs Pharma UK (Pharmanovia) for seizure therapy Libervant (diazepam) Buccal Film.
• The expanded agreement will cover the rest of the world, excluding the U.S., Canada, and China.
• The original licensing agreement, signed in September 2022, covered the EU, the U.K, Sweden, Switzerland, Norway, and countries in the Middle East and North Africa (MENA), according to the company.
• Under the expanded deal, Aquestive will be the sole maker and supplier of the product, while Pharmanovia will be responsible for all regulatory and commercialization activities.
• Aquestive will receive an undisclosed upfront fee and, if approved, milestone payments, and royalties on net sales of the drug in the licensed territories.
• Libervant, which is an inside the cheek administered film formulation of diazepam, a benzodiazepine aimed for treating intermittent, stereotypic episodes of frequent seizure activity (seizure clusters) which are different from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.
• AQST +0.65% to $0.90 premarket March 29

For further details see: